Highlights

  • Racura Oncology (ASX:RAC) dosed the first patient in its Phase 1a/b HARNESS-1 trial evaluating RC220.
  • The trial is assessing RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer.
  • RC220 is being developed from a reformulated version of bisantrene.
  • Safety, dose escalation and future clinical data remain the key development milestones.

Racura Oncology (ASX:RAC) has advanced its lead oncology program into human testing after dosing the first patient in its HARNESS-1 clinical trial.

The trial evaluates RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer, targeting treatment resistance that can develop after initial response to targeted therapies.

The milestone begins clinical evaluation of the combination, although efficacy remains unproven at this early stage.

What Happened?

On 25 June 2026, Racura Oncology announced that the first patient had been dosed in HARNESS-1 at Monash Health in Clayton, Victoria.

The patient received RC220 at a starting dose of 50 mg/m² through intravenous administration, with no adverse events reported during or after infusion.

HARNESS-1 is a multi-centre Phase 1a/b trial evaluating RC220 in combination with osimertinib, a tyrosine kinase inhibitor used in EGFR-mutant non-small cell lung cancer.

Additional clinical sites are expected to participate as recruitment progresses.

The milestone follows the company’s transition from Race Oncology to Racura Oncology in December 2025, while the underlying pipeline and RC220 program remain unchanged.

Why It Matters

EGFR-mutant non-small cell lung cancer has become a major area of targeted cancer treatment, but resistance to EGFR inhibitors remains a significant challenge.

Osimertinib can produce initial tumour responses, but many patients eventually experience disease progression as resistance mechanisms emerge.

HARNESS-1 is designed to investigate whether RC220 can complement osimertinib by targeting additional cancer pathways.

RC220’s active molecule, (E,E)-bisantrene, is being developed as a therapy targeting G-quadruplex structures involved in cancer-related gene regulation.

The company’s approach is focused on combining transcriptional pathway disruption with targeted EGFR inhibition.

The Numbers

HARNESS-1 is structured as a staged Phase 1a/b study.

The initial dose escalation includes single-patient cohorts at:

  • 50 mg/m².
  • 100 mg/m².
  • 150 mg/m².

The study will then progress to larger cohorts to establish the maximum tolerated dose.

The escalation phase is expected to involve approximately 12 to 40 participants, followed by a randomised Phase 1b expansion of around 40 patients.

Patient selection uses circulating tumour DNA (ctDNA) screening to identify eligible participants.

Racura has reported raising A$34.3 million over approximately two years to support three clinical programs.

As at 31 March 2026, the company reported approximately A$19.38 million in cash reserves.

The company has indicated this funding supports its clinical programs towards 2028 based on then-current spending rates.

The Bigger Picture

Racura Oncology’s strategy is based on developing RC220 across multiple therapeutic areas.

The company’s pipeline includes:

  • HARNESS-1, evaluating RC220 in EGFR-mutant lung cancer.
  • CPACS, evaluating cardioprotection in cancer patients receiving doxorubicin.
  • A Phase 3 acute myeloid leukaemia (AML) program.

The approach is based on reformulating and repositioning bisantrene, a molecule with historical development experience.

Developing the same underlying asset across different indications may provide multiple clinical pathways, although it also requires Capital allocation across several programs.

The Bull Case

The positive case for Racura Oncology (ASX:RAC) is based on advancing RC220 through multiple clinical applications.

HARNESS-1 targets a defined medical challenge in EGFR-mutant lung cancer where resistance to targeted therapies remains a major issue.

The combination approach with osimertinib provides a mechanism-based rationale for further investigation.

The company’s multi-program strategy may provide additional opportunities if RC220 demonstrates clinical activity across different disease settings.

Risks Investors Should Understand

Racura Oncology (ASX:RAC)’s Business faces risks including early-stage clinical outcomes, safety limitations, funding requirements and regulatory uncertainty.

Phase 1 trials primarily assess safety and dosing rather than proving treatment effectiveness.

Small patient cohorts mean individual safety events or limited activity signals can significantly influence future development decisions.

The ctDNA-based patient selection approach may improve trial targeting but could also affect recruitment speed.

Although the company has indicated funding support across multiple programs, running several Clinical Trials simultaneously requires significant capital.

What Comes Next?

The next milestones involve safety and dose escalation results from HARNESS-1.

Investors will monitor progression through the 50 mg/m², 100 mg/m² and 150 mg/m² cohorts, additional trial site activation and future decisions regarding expansion cohorts.

Updates from the CPACS cardioprotection trial and Phase 3 AML program will also remain relevant.

Conclusion

Racura Oncology (ASX:RAC) has moved RC220 into clinical testing through the first patient dose in the HARNESS-1 lung cancer trial.

The program provides an opportunity to evaluate whether RC220 can complement targeted EGFR therapy and address resistance mechanisms.

However, the trial is at an early stage, and future value depends on safety outcomes, efficacy signals and progression through later development phases. The first patient dose establishes the pathway, but the key clinical questions remain ahead.